Montana has advanced its plan to become a hub for experimental medicine, allowing biotech companies to apply for approval of drugs that have undergone preliminary testing. For a fee of $12,500, companies can submit their treatments to a new review board. Once approved, these drugs can be sold through experimental treatment clinics, with the first expected to open by year's end. This "right-to-try" legislation is unique, theoretically making access available to anyone who consents and can afford it.

While some, particularly in the longevity community, view this as a hopeful prospect, others deem it unethical and dangerous. The legislation offers a glimmer of hope for individuals like Kris De Vault, whose son Brody suffers from a rare condition for which no cure exists. De Vault is pursuing a company developing an early-stage drug that has only been tested in animals and a small group of healthy adults.

The article also touches on other technology news, including AI advancements by companies like Anthropic and Google, the growing investment in AI infrastructure by major tech firms, and the challenges of drone warfare. Additionally, it highlights the past effectiveness of the US Office of Technology Assessment in evaluating emerging technologies and the current calls for its revival.